ExScientia Ltd

Exscientia Plc operates as an AI-driven pharmatech company which is engaged in designing and developing patient-based drugs. The firm has designed three drugs that are in phase 1 human clinical trials. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ExScientia reports robust Q4 earnings, poised for precision medicine growth

ExScientia's Q4 2022 earnings call highlighted strong financial performance, key collaborations, and advancements in pipeline programs. The company's focus on AI-driven precision medicine and solid cash position bode well for future growth. Challenges in program management and cost control exist, but opportunities for innovation and partnerships are abundant.

ExScientia reports 15% revenue growth, poised for precision medicine leadership

ExScientia Ltd delivered strong financial performance with a 15% increase in quarterly revenue and a robust cash position, driven by successful product launches and cost-saving initiatives.
The company's focus on personalized medicine, innovative product development, and strategic financial management positions it well for future growth and market leadership.
While facing challenges in molecule differentiation and cost efficiency, ExScientia has opportunities to leverage biomarkers, advance clinical programs, and expand market presence.

ExScientia advances clinical trials and precision medicine with strong financials

ExScientia's Q2 2023 earnings call showcased progress in clinical trials, precision medicine, and AI integration, supported by a strong financial position.
The company's focus on innovation, cost efficiency, and strategic partnerships positions them well for future growth and advancements in drug discovery.
Challenges lie in managing milestone payments, operational complexities, and staying competitive through biologics investments and partnerships.
Opportunities abound in expanding collaborations, attracting industry interest, and unveiling advancements in biologics for pipeline growth from 2024 onwards.

ExScientia excels in Q3, poised for growth in precision medicine

ExScientia's Q3 performance reflects progress in oncology programs, financial strength, and a focus on precision drug design and partnerships.
The company's strengths lie in its robust cash position, innovative approach to drug design, and operational efficiency influenced by past projects.
Challenges include market adaptability, program prioritization, and maintaining competitiveness, while opportunities exist in advancing the pipeline and leveraging partnerships for growth.

ExScientia reports robust Q4 earnings, eyes growth through innovation

ExScientia's Q4 2023 earnings call showcases strong financial and operational performance.
The company's focus on innovation, partnerships, and efficiency drives growth.
Challenges include competition, innovation sustainability, and quality maintenance.
Opportunities lie in business development, automation, and efficient drug creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in the following upcoming investor conferences in June: Barclays Digital and Disruptive Technology Conference. Panel on Tuesday, June 11, 2024 at 9:45 a.m. BST in London, England Goldman Sachs 45th Annual Global Healthcare Conference. Fireside chat on Tuesday, June 11, 2024 at 3:20 p.m. EDT (8:20 p.m. BST) in Miami, Florida Live webcasts of the Barclays and Gold.

Exscientia to Present at Upcoming Investor Conferences in June

NEW YORK , May 29, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Exscientia plc (NASDAQ: EXAI). Shareholders who purchased shares of EXAI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Exscientia plc Sued for Securities Law Violations - Contact The Gross Law Firm Before June 25, 2024 to Discuss Your Rights - EXAI

Exscientia plc (NASDAQ:EXAI ) Q1 2024 Earnings Conference Call May 21, 2024 8:30 AM ET Company Participants Chinedu Okeke - Associate Director-Strategy, IR David Hallett - Interim CEO, Chief Scientific Officer Ben Taylor - CFO, Chief Strategy Officer Conference Call Participants Alec Stranahan - Bank of America Vikram Purohit - Morgan Stanley Peter Lawson - Barclays Operator Hello, everyone. My name is Sarah, and I will be your conference operator today.

Exscientia plc (EXAI) Q1 2024 Earnings Call Transcript

Roundhill Generative AI & Technology ETF

Lantern Pharma

One of the hottest investment trends to jump on at the moment is machine learning stocks to buy. Valued at about $79.3 billion at the moment, it's expected to balloon to $503.4 billion by the time 2030 rolls around, according to Statista.

The 3 Best Machine Learning Stocks to Quadruple Your Money by 2035

Exscientia (EXAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Exscientia (EXAI) Upgraded to Buy: Here's What You Should Know

NEW YORK , May 22, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Exscientia p.l.c (NASDAQ: EXAI) between March 23, 2022 and February 12, 2024, both dates inclusive (the "Class Period"), of the important June 25, 2024 lead plaintiff deadline. SO WHAT: If you purchased Exscientia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action - EXAI

Exscientia plc's stock has underperformed the biotechnology and IT sectors, despite owning a tech platform attracting big pharma. The company uses AI to accelerate drug development and reduce time to market, potentially improving success rates. The partnerships with major pharmaceutical companies are generating cash inflows and the potential for future royalties.

Exscientia: Drug Discovery Platform Attracting Partners And Cash

OXFORD, U.K.--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI): Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the first quarter 2024, are summarised below. Exscientia will host a conference call Tuesday, May 21 at 1:30 p.m. BST / 8:30 a.m. EDT. “With the ramp up of activities at our automation lab, we are beginning to see the transformative power of fully integrating AI drug design with the sheer capacity of comprehensive robotic au.

Exscientia Business Update for First Quarter 2024

NEW YORK , May 21, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Exscientia plc (NASDAQ: EXAI). Shareholders who purchased shares of EXAI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Shareholders of Exscientia plc Should Contact The Gross Law Firm Before June 25, 2024 to Discuss Your Rights - EXAI

LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exscientia plc ("Exscientia" or "the Company") (NASDAQ:EXAI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 23, 2022 and February 12, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 25, 2024.

IMPORTANT INVESTOR ALERT: The Schall Law Firm Encourages Investors in Exscientia plc with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exscientia plc ("Exscientia" or "the Company") (NASDAQ:EXAI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 23, 2022 and February 12, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 25, 2024.

IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Encourages Investors in Exscientia plc with Losses to Contact the Firm

NEW YORK, NY / ACCESSWIRE / May 16, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=80306&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Exscientia plc(EXAI) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More

NEW YORK , May 15, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Exscientia p.l.c (NASDAQ: EXAI) between March 23, 2022 and February 12, 2024, both dates inclusive (the "Class Period"), of the important June 25, 2024 lead plaintiff deadline. SO WHAT: If you purchased Exscientia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action - EXAI

NEW YORK, NY / ACCESSWIRE / May 15, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=80050&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Exscientia plc (EXAI) should contact Levi & Korsinsky about pending Class Action - EXAI

NEW YORK, NY / ACCESSWIRE / May 15, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=79994&wire=1 or contact Joseph E. Levi, Esq.

June 25, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - EXAI

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 21, 2024, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. BST / 8:30 a.m. EDT to provide a business update and review financial results. A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company's website at investors.exscientia.ai. Alternatively, t.

Exscientia to Report First Quarter 2024 Financial Results on May 21, 2024

NEW YORK--(BUSINESS WIRE)-- #Investigation--The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of those who acquired Exscientia p.l.c. (“Exscientia” or the “Company”) (NASDAQ: EXAI) securities during the period of March 23, 2022 through February 12, 2024, inclusive (“the Class Period”). Investors have until June 25, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. [Click.

Kirby McInerney LLP Reminds Exscientia p.l.c. (EXAI) Investors of Class Action Filing and Encourages Investors to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)---- $EXAI #EXAI--Robbins LLP is Investigating the Allegations that Exscientia plc's (EXAI) Former CEO's Conduct Violated the Company's Code of Business Conduct.

EXAI Stockholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Against Exscientia plc

NEW YORK, NY / ACCESSWIRE / May 9, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=79102&wire=1 or contact Joseph E. Levi, Esq.

Shareholders of Exscientia plc Should Contact Levi & Korsinsky Before June 25, 2024 to Discuss Your Rights – EXAI

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming June 25, 2024 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Exscientia p.l.c. (“Exscientia” or the “Company”) (NASDAQ: EXAI) securities between March 23, 2022 and February 12, 2024, inclusive (the “Class Period”). Investors suffering losses on their Exscientia investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their l.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Exscientia p.l.c.

NEW YORK , May 8, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Exscientia p.l.c (NASDAQ: EXAI) between March 23, 2022 and February 12, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action - EXAI

NEW YORK, NY / ACCESSWIRE / May 8, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=78825&wire=1 or contact Joseph E. Levi, Esq.

Exscientia plc Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 25, 2024 to Discuss Your Rights – EXAI

NEW YORK, NY / ACCESSWIRE / May 7, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=78598&wire=1 or contact Joseph E. Levi, Esq.

Exscientia plc Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 25, 2024 to Discuss Your Rights – EXAI

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Exscientia p.l.c. (“Exscientia” or the “Company”) (NASDAQ: EXAI) securities between March 23, 2022 and February 12, 2024, inclusive (the “Class Period”). Exscientia investors have until June 25, 2024 to file a lead plaintiff motion. If you suffered a loss on your Exsc.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Exscientia p.l.c. (EXAI) Investors

NEW YORK , May 7, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Exscientia plc (NASDAQ: EXAI). Shareholders who purchased shares of EXAI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

News for ExScientia Ltd Stock (EXAI)